BiologicsMD is based in Fayetteville, Arkansas and was formed in
2010 to accelerate the development of academic discoveries into new
medications that will enhance people's lives. The company won
over $600,000 in cash, awards, and investments at six major
entrepreneurial business plan competitions. In 2011 the
firm was selected to receive a $2.3 million U.S. Department of
Defense research contract to continue research on its innovative
osteoporosis compound. The award was through the U.S.
Department of Defense Peer Reviewed Medical Research Program of the
Office of the Congressionally Directed Medical Research Programs
(CDMRP). This program received more than 600 applications and
fewer than 10 percent were recommended for funding.
The company's lead compound, PTH-CBD™, is focused on helping
patients avoid the devastating effects of osteoporosis. The
next steps in the PTH-CBD development program include manufacturing
process development, preclinical toxicology testing, preparation
and submission of an Investigation New Drug (IND) application, and
the completion of a Phase I clinical trial. PTH-CBD™
promises five times the efficacy of available bisphosphonate
treatments with fewer side effects. According to the National
Osteoporosis Foundation, one in two women and one in four men will
be diagnosed with osteoporosis in their lifetime.